Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2017 Standout
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Guidelines for the Management of Spontaneous Intracerebral Hemorrhage
2015 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation
2007
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary
2014 Standout
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
2010
The Mode Selection Trial (MOST) in sinus node dysfunction: Design, rationale, and baseline characteristics of the first 1000 patients
2000
Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients
2009
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
2001 Standout
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation
2010 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation
2010
Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach
2009 Standout
Oral Anticoagulant Therapy
2012 Standout
Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention
2002
Antithrombotic Therapy for VTE Disease
2016 Standout
Lenient versus Strict Rate Control in Patients with Atrial Fibrillation
2010
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
2010
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Edoxaban for the long‐term treatment of venous thromboembolism: rationale and design of the Hokusai‐venous thromboembolism study – methodological implications for clinical trials
2013
Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients
2011
Trans Fatty Acids and Cardiovascular Disease
2006 Standout
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial
2010
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
2011 Standout
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Novel Oral Anticoagulants in Atrial Fibrillation: A Meta‐analysis of Large, Randomized, Controlled Trials vs Warfarin
2013
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
GRADE guidelines: 3. Rating the quality of evidence
2011 Standout
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
2010 Standout
Use of electron beam tomography data to develop models for prediction of hard coronary events
2001
New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs
2010
Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review
2007
Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin Therapy
2006
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation
2010
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
2003 Standout
Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk?
2010
Death and Disability from Warfarin-Associated Intracranial and Extracranial Hemorrhages
2007
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation
2006
Idarucizumab for Dabigatran Reversal
2015 Standout
Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification
2010
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials
2006
Coronary Calcium as a Predictor of Coronary Events in Four Racial or Ethnic Groups
2008 Standout
Quality of Life and Clinical Outcomes in Elderly Patients Treated with Ventricular Pacing as Compared with Dual-Chamber Pacing
1998
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
2008 Standout
Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation
2012
Endothelial function
2002
Development of a Contemporary Bleeding Risk Model for Elderly Warfarin Recipients
2006
Antithrombotic Therapy for Atrial Fibrillation
2012
Management of atrial fibrillation in patients with heart failure
2006
Antithrombotic Therapy in Atrial Fibrillation
2008
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
Role of Endothelial Dysfunction in Atherosclerosis
2004 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Machine Learning in Medicine
2015 Standout
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2019 Standout
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
2011 Standout
Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial
2018
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons
2019 Standout
Risk-Adjusted Percent Time in Therapeutic Range as a Quality Indicator for Outpatient Oral Anticoagulation
2010
Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis
2019
Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation
2012
ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities
2008 Standout
Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery
2006
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2020 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease
2017 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Improved anticoagulation with a weight-adjusted heparin nomogram in patients with acute coronary syndromes: A randomized trial
1995
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
2012 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
2005 Standout
Predictors of Initial Nontherapeutic Anticoagulation With Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction
2009
Replacement of Dietary Saturated Fatty Acids by Trans Fatty Acids Lowers Serum HDL Cholesterol and Impairs Endothelial Function in Healthy Men and Women
2001
Works of Gregory C. Flaker being referenced
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study
2005
Are Statins Being Underdosed in Clinical Practice?
2005
Does Dual Chamber or Atrial Pacing Prevent Atrial Fibrillation? The Need for a Randomized Controlled Trial
1992
Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: A mechanism for reducing clinical events?
2000
Atrial Fibrillation after Coronary Bypass: Etiology and Pharmacologic Prevention
2002
Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
2008
DABIGATRAN VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION - AN ANALYSIS OF PATIENTS UNDERGOING CARDIOVERSION
2010
Factors Affecting Bleeding Risk During Anticoagulant Therapy in Patients With Atrial Fibrillation: Observations From the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study
2005
Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. TIMI 4 investigators. Thrombolysis in Myocardial Infarction.
1994